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Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder caused by complex interaction of
genetic and environmental factors. Besides mutations in the filaggrin gene, leading to impaired skin barrier
function, variation in genes encoding additional skin proteins has been suggested to contribute to disease risk.
Laminin 5, playing an important role in skin integrity, is composed of three subunits encoded by the LAMA3, LAMB3
and LAMC2 genes in which biallelic mutations cause epidermolysis bullosa junctionalis. We aimed at evaluating the
role of variation in the LAMA3, LAMB3 and LAMC2 genes for AD pathogenesis.
Methods: 29 single nucleotide polymorphisms (SNPs) were genotyped in the three genes in a German AD case–control
cohort comprising 470 unrelated AD patients and 320 non-atopic controls by means of restriction enzyme digestion.
Allele, genotype and haplotype frequencies were compared between cases and controls using chi-square testing and the
Haploview software.
Results: Several SNPs in the LAMA3 gene showed significant association with AD in our cohort (p <0.01), while we did
not detect association with variations in the LAMB3 and LAMC2 genes. Haplotype analysis additionally revealed several
significantly associated haplotypes in the LAMA3 gene. Due to extensive linkage disequilibrium, though, we were not able
to further differentiate the specific disease causing variation(s) in this region.
Conclusions: We established the LAMA3 gene as novel potential susceptibility gene for AD. Additional studies in
independent cohorts are needed to replicate these results.
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Atopic dermatitis (AD) is a chronic inflammatory skin
disorder caused by complex interaction between genetic
and environmental factors [1]. Besides dysregulated im-
mune mechanisms that have long been suspected to play
a major role for AD pathogenesis, the impact of an in-
tact skin barrier in the protection against AD has gained
increasing attention over the recent years [2]. In particu-
lar, the role of filaggrin, a major structural protein in the
stratum corneum of the epidermis, has been extensively* Correspondence: sabine.hoffjan@rub.de
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unless otherwise stated.studied. Mutations in the FLG gene, located in the epi-
dermal differentiation complex (EDC) on chromosome
1q21 [3], have consistently been associated with early-
onset persistent AD [4]. It could be demonstrated that
FLG mutations constitute the most significant known
risk factor for AD development so far [5]. However, im-
paired skin barrier function has also been shown in AD
patients without FLG mutations [6], suggesting that vari-
ation in genes encoding additional skin proteins may
play a role in AD pathogenesis.
Laminin 5 is another protein that plays an important
role for skin integrity [7]. It is comprised of three differ-
ent subunits, built by the LAMA3 (alpha-3), LAMB3
(beta-3) and LAMC2 (gamma-2) polypeptide chains.ral Ltd. This is an Open Access article distributed under the terms of the Creative
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necting dermis and epidermis and induces adhesion,
spreading and migration of human keratinocytes [8].
The three polypeptide chains are encoded by the
LAMA3, LAMB3 and LAMC2 genes on chromosomes
18q11.2, 1q32.2 and 1q25.3, resp. [9]. Biallelic mutations
in each of these three genes are known to cause epidermo-
lysis bullosa junctionalis, a severe (type Herlitz) or less se-
vere (type Non-Herlitz) skin disorder characterized by
blisters and erosions of the skin [10]. Furthermore, lam-
inin 5 synthesis is elevated during acute wound healing in
healthy individuals [11].
Given the important role of mutations in skin barrier
proteins in AD pathogenesis, we hypothesized that vari-
ation in one or more of the laminin 5 subunits may also
confer risk for AD. Therefore we evaluated 29 single nu-
cleotide polymorphisms (SNPs) in the three genes in a
German AD case–control cohort and present first evi-
dence that the LAMA3 gene may be a novel susceptibil-
ity gene for AD.
Methods
Subjects
470 unrelated patients with AD with a mean age of 19 ±
15 years (median 11 years) were recruited by a consult-
ant specialist for AD (Q.P., Gladbeck, Germany) as de-
scribed before [12]. AD diagnosis was established based
on the criteria by Hanifin and Rajka [13]. Since the risk
remains very high for primarily asymptomatic children
to develop an allergic disease during childhood or even
adulthood [14,15], we chose to use non-allergic adults as
a control group. Therefore, 320 individuals of at least
40 years (mean age 62 ± 11 years, median 63 years) that
had neither self-reported allergies or allergic symptoms
nor first degree relatives with allergic diseases were re-
cruited in the same private practice as the patients. The
controls further underwent clinical examination in order
to exclude symptoms of AD, asthma or allergic rhinitis
(see [12]). All participants were Germans of European
ancestry and gave informed consent prior to enrolment.
The Declaration of Helsinki protocols were followed and
the study was approved by the Ethics Committee of the
Ruhr-University Bochum.
Genotyping
DNA of AD patients and controls was extracted as de-
scribed before [16]. We selected 29 SNPs in the three
genes (17 in the LAMA3 gene, 8 in LAMB3, and 4 in
LAMC2) that represented the haplotype block struc-
tures according to HapMap [17]. Genotyping was per-
formed by polymerase chain reaction (PCR) followed
by restriction enzyme digestion. PCR was done in a
total volume of 10 μl, containing 40 ng DNA, 200 mmol
of each dNTP, 1.5-3 mmol MgCl2, 5 pmol of eachprimer, and 0.5 U Taq-DNA-polymerase (Genecraft,
Münster, Germany) on the RoboCycler or Biometra T
cycler (Stratagene, Heidelberg, Germany and Biometra
GmbH, Göttingen, Germany, respectively). After two
initial cycles at 6° C and 3°C above the annealing
temperature, 28–32 cycles of 95°C (30 sec), annealing
temperature (30 sec) and 72°C (30 sec) were run. PCR
products were subsequently digested with the respect-
ive restriction enzyme, the fragments separated on
2.5%-3.5% agarose gels in 1xTBE buffer (30–60 min,
200 V) and visualized with ethidium bromide (0.5% [w/v]).
Additional information about primer sequences, PCR
conditions and restriction enzymes is summarized in
Additional file 1.
Statistics
Genotype and allele frequencies were compared be-
tween AD patients and controls according to the χ2
method; the significance threshold was set at p < 0.05.
We evaluated every SNP for deviations from Hardy-
Weinberg equilibrium (HWE) using the deFinetti pro-
gram [18]. The program Haploview 4.0 [19] was used
to estimate haplotype frequencies and test for haploty-
pic association. We applied Bonferroni correction for
multiple tests; however, since this approach has been
controversially discussed for genetic case–control stud-
ies [20], especially if several tightly linked SNPs within
one gene are analyzed as in the present study, we also
present the uncorrected p-values and discuss them as
hypothesis-generating.
Results
All 29 SNPs showed genotypic distributions according to
HWE. Of the 17 SNPs chosen for the LAMA3 gene, ten
showed significant associations (p < 0.01 in the uncor-
rected analysis) with AD in the present cohort. The most
significant results that also survived Bonferroni correc-
tion were obtained for rs8083184 and rs1711450, both
located in the promoter region of LAMA3 (p = 0.0003,
pcorr = 0.0087, Table 1; full genotype data is presented in
Additional file 2). A high degree of linkage disequilib-
rium (LD) was observed for the SNPs in the LAMA3
gene region (Figure 1). Significant association extended
into the 5′ region of LAMA3, including rs1613739
which is located in the neighbouring ANKRD29 gene.
Two other SNPs in ANKRD29 (rs7238623 and rs8096061),
however, did not show significant association results.
Haplotype analyses revealed the existence of two haplo-
blocks (Figure 1) with a common haplotype in block 1 that
was highly significantly associated with AD (61.9% in cases
vs. 51.1% in controls, p = 2.94×10−5, Table 2).
In the LAMB3 gene, neither single SNP nor haplotype
analyses revealed significant association with AD in the
present cohort (Table 1; haplotype data not shown). In
Table 1 Allele frequencies of LAMA3, LAMB3 and LAMC2 polymorphisms in AD patients and controls
Gene SNP Location Amino acid
exchange
MAF in AD
patients
MAF in
controls
Uncorrected
p-value
Corrected
p-value*
LAMA3 18q11.2 rs7238623 5′UTR (ANKRD29) - 0.107 0.083 0.123 n.s.
rs8096061 5′UTR (ANKRD29) - 0.036 0.044 0.441 n.s.
rs1613739 5′UTR (ANKRD29) - 0.143 0.200 0.003 0.087
rs12960692 5′UTR - 0.439 0.454 0.568 n.s.
rs8083184 5′UTR - 0.297 0.386 0.0003 0.0087
rs1711450 5′UTR - 0.319 0.410 0.0003 0.0087
rs1711451 Intron 1 - 0.336 0.408 0.005 0.145
rs4387667 Intron 2 - 0.336 0.408 0.005 0.145
rs2337187 Intron 2 - 0.250 0.325 0.001 0.029
rs1316950 Intron 2 - 0.331 0.407 0.003 0.087
rs4044148 Intron 12 - 0.234 0.395 0.007 0.203
rs1262340 Intron 44 - 0.143 0.196 0.006 0.174
rs734731 Intron 55 - 0.079 0.104 0.096 n.s.
rs1541836 Intron 59 - 0.086 0.106 0.195 n.s.
rs1786310 Intron 62 - 0.076 0.103 0.047 n.s.
rs1154232 Exon 65 Asn2815Lys 0.187 0.225 0.069 n.s.
rs2288592 Intron 69 - 0.278 0.345 0.005 0.145
LAMB3 1q32.2 rs2566 3′UTR - 0.283 0.271 0.611 n.s.
rs2009292 Intron 18 - 0.323 0.336 0.617 n.s.
rs3179860 Exon 18 Leu891Leu 0.161 0.144 0.375 n.s.
rs12748250 Exon 17 Met852Leu 0.167 0.150 0.361 n.s.
rs2072938 Intron 11 - 0.172 0.174 0.901 n.s.
rs4844863 Intron 8 - 0.157 0.160 0.889 n.s.
rs2236891 Intron 8 - 0.129 0.101 0.094 n.s.
rs2236892 Intron 8 - 0.165 0.178 0.517 n.s.
LAMC2 1q25.3 rs483783 Intron 1 - 0.490 0.467 0.362 n.s.
rs601508 Intron 1 - 0.476 0.440 0.158 n.s.
rs2274980 Exon 3 Ser99Ser 0.166 0.173 0.723 n.s.
rs11586699 Exon 3 Thr124Met 0.077 0.062 0.263 n.s.
*after Bonferroni correction for 29 SNPs; n.s.: not significant; bold: significant results.
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however, haplotype analyses revealed the existence of a
rare protective haplotype (4% in cases vs. 6.9% in con-
trols, p = 0.01; Table 3).
Discussion
To our knowledge, this is the first report of an associ-
ation of AD with variation in the LAMA3 gene, encod-
ing the alpha-chain of laminin 5. In a well-characterized
German case–control cohort, we found significant asso-
ciation of both allelic and haplotypic frequencies in this
gene with AD, suggesting that it may constitute a novel
susceptibility gene for this frequent skin disease.
Of the 19 SNPs evaluated across the LAMA3 gene, ten
showed genotypic or allelic association with AD at p <0.01 (uncorrected values). Due to the extensive LD evi-
dent at the LAMA3 locus we were not able to further
differentiate the specific disease causing variation(s) in
this region. Significant association extended into the 5′
neighbouring gene ANKRD29, but additional SNPs in
this gene did not show association with AD. The bio-
logical function of ANKRD29, encoding the ankyrin repeat
domain-containing protein 29, is not yet known; however,
for another protein of the same family, ANKRD17, a role
in anti-bacterial innate immune pathways has been sug-
gested [21]. For the gene located 3′ of LAMA3 (TTC39C),
encoding the tetratricopeptide repeat protein 39C, the
biological function is not yet clear either, and since the
most significant results for LAMA3 were at the 5′ end of
this large gene, we did not evaluate additional SNPs in the
LAMA3ANKRD29 TTC39C
***** * * * * ** *
Figure 1 Haploblock structure of the LAMA3 region as revealed by Haploview 4.0 [19]. *SNPs associated with AD at p < 0.01 (uncorrected
values) **SNPs associated with AD at p < 0.001 (uncorrected values).
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clude that the observed association with AD may be due
to LD with a susceptibility variant in another gene in this
region, our data highly points to LAMA3 as susceptibility
gene for AD in the 18q11.2 region. SNPs in the genes en-
coding the beta- and gamma-chains of laminin 5, on the
other hand, did not show convincing evidence for associ-
ation with AD in this analysis. However, haplotype analysis
suggested the existence of a rare protective haplotype in
LAMC2.
The main role of laminin 5 in normal tissues is the
maintenance of epithelial-mesenchymal cohesion in tis-
sues exposed to external forces, such as skin and stratified
squamous mucosa [22]. Genetic variation in laminin 5
components may thus contribute to reduced skin integrity
and barrier function, as has been observed for FLG muta-
tions [5], even though the exact underlying mechanisms
still have to be elucidated. In each of the three genes ana-
lysed here, rare null mutations are known to cause epider-
molysis bullosa junctionalis, a severe autosomal recessiveskin disorder characterized by the development of blisters
and skin erosions in response to minor injury or friction
[10]. In contrast, we observed association of common
variation in LAMA3 with the common complex disorder
AD. This phenomenon is in line with findings for the
SPINK5 gene, in which null mutations cause autosomal
recessive Netherton syndrome while common variations
have been associated with AD [23].
Our association results further contribute to the hy-
pothesis that an intact skin barrier function plays a key
part in AD pathogenesis. Additional to the established
role of FLG mutations [24], associations with some other
skin-related genes have been described recently. For ex-
ample, mutations in the claudin-1 gene (CLDN1), encod-
ing a major tight junction protein in the granular layer
of the epidermis, were associated with AD in North
American cohorts of both European and African Ameri-
can origin [25]. Further, polymorphisms near the OVOL1
and ACTL9 genes, both involved in epidermal prolifera-
tion and differentiation, showed genome-wide significant
Table 2 Frequencies and p-values of LAMA3 haplotypes in
AD patients and controls
Haplotype Frequency in AD
patients (n = 470)
Frequency in
controls (n = 320)
p-value
Block 1
1112122 0.619 0.511 2.9x10−5
2221211 0.134 0.182 0.0114
2221212 0.086 0.088 0.8954
2222222 0.060 0.070 0.4447
1212122 0.023 0.019 0.607
1122222 0.022 0.016 0.4152
2221222 0.016 0.021 0.4906
2112122 0.012 0.025 0.0465
Block 2
12121 0.718 0.650 0.0043
12112 0.113 0.110 0.8506
12212 0.074 0.106 0.0305
21122 0.079 0.093 0.3379
12122 0.007 0.022 0.0083
Bold: significant results.
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data, including 5,606 AD patients and 20,565 controls
[26]. In a study cohort comprising AD patients from
Germany, Poland and the Czech Republic, a 24-bp dele-
tion in the gene encoding small proline-rich protein 3
(SPRR3), located within the EDC, was significantly associ-
ated with disease risk [27]. On the other hand, a deletion
of the cornified envelope 3B and 3C genes within in the
EDC was not associated with AD in a European cohort
[28]. All of these results still await replication in independ-
ent cohorts. Altogether, though, evidence is accumulating
that additional genes involved in epidermal differentiation
and stability may be important for AD pathogenesis.
We are conscious of the fact that the cohort sizes of the
present study are comparatively small so that theTable 3 Frequencies and p-values of LAMC2 haplotypes in
AD patients and controls
Haplotype Frequency in AD
patients (n = 470)
Frequency in
controls (n = 320)
p-value
1221 0.356 0.341 0.5252
2121 0.347 0.343 0.8557
2111 0.099 0.086 0.3998
1222 0.068 0.053 0.2136
1121 0.040 0.069 0.0102
1111 0.037 0.058 0.0493
2211 0.022 0.016 0.4027
2221 0.015 0.014 0.8668
Bold: significant results.statistical power is only moderate. Furthermore, only for
two SNPs in LAMA3 results remained significant after
strict Bonferroni correction for multiple testing, leaving
open the risk for false-positive results. However, the
Bonferroni correction has been controversially discussed
for genetic case–control studies [20], especially if several
tightly linked SNPs within one gene are analyzed, as was
the case in the present study. Therefore, we regard the
results as hypothesis-generating and strongly encourage
replication in additional cohorts.
Conclusions
We presented initial evidence for association of LAMA3
variation with AD, suggesting that variation in this gene
may contribute to skin fragility and impaired barrier
function underlying AD pathogenesis. Additional studies
in independent populations as well as functional analyses
of the associated variations appear warranted to replicate
or extend these findings, since the genetic risk factors
for AD might be increasingly included into prognostic
and therapeutic strategies in the future. In more detail,
an integrated approach including genotypic and pheno-
typic information as well as genetic and biological bio-
markers has been proposed for example to identify
patients who are prone to develop persistent AD and/ or
additional asthma and start early intervention [29]. Fur-
ther, therapeutic strategies targeting the skin barrier
function are already under way [30]. Thus, elucidating
the complex genetic background of AD is essential for
paving the way towards a more individualized therapy in
the future.
Additional files
Additional file 1: Primers, PCR conditions and restriction enzymes
used for genotyping of polymorphisms in the LAMA3, LAMB3 and
LAMC2 genes.
Additional file 2: Complete single SNP association results.
Abbreviations
AD: Atopic dermatitis; EDC: Epidermal differentiation complex; HWE: Hardy-
Weinberg equilibrium; LD: Linkage disequilibrium; SNP: Single nucleotide
polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SS was in charge of study design and statistical analysis and drafted the
manuscript. QP and EPP were involved in patient recruitment and helped to
draft the manuscript. JTE and SH conceived of the study, participated in its
design and coordination and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgments
We thank Maike Kallenbach, Natascha Wirkus, Monika Harazin and Katharina
Batzke for technical assistance and the patients for their cooperation in this
study.
Stemmler et al. BMC Dermatology 2014, 14:17 Page 6 of 6
http://www.biomedcentral.com/1471-5945/14/17Author details
1Department of Human Genetics, Ruhr-University, Universitätsstrasse 150,
44801 Bochum, Germany. 2Private medical practice, Gladbeck, Germany.
3Department of Neuroanatomy and Molecular Brain Research,
Ruhr-University Bochum, Bochum, Germany. 4Faculty of Health, Witten/
Herdecke University, Witten, Germany.
Received: 3 June 2014 Accepted: 23 October 2014
Published: 3 November 2014
References
1. Holloway JW, Yang IA, Holgate ST: Genetics of allergic disease. J Allergy
Clin Immunol 2010, 125:S81–S94.
2. Boguniewicz M, Leung DY: Atopic dermatitis: a disease of altered skin
barrier and immune dysregulation. Immunol Rev 2011, 242:233–246.
3. Kypriotou M, Huber M, Hohl D: The human epidermal differentiation
complex: cornified envelope precursors, S100 proteins and the ‘fused
genes’ family. Exp Dermatol 2012, 21:643–649.
4. Irvine AD, McLean WH, Leung DY: Filaggrin mutations associated with
skin and allergic diseases. N Engl J Med 2011, 365:1315–1327.
5. McAleer MA, Irvine AD: The multifunctional role of filaggrin in allergic
skin disease. J Allergy Clin Immunol 2013, 131:280–291.
6. Jakasa I, Koster ES, Calkoen F, McLean WH, Campbell LE, Bos JD, Verberk
MM, Kezic S: Skin barrier function in healthy subjects and patients with
atopic dermatitis in relation to filaggrin loss-of-function mutations.
J Invest Dermatol 2011, 131:540–542.
7. Nishiyama T, Amano S, Tsunenaga M, Kadoya K, Takeda A, Adachi E,
Burgeson RE: The importance of laminin 5 in the dermal-epidermal
basement membrane. J Dermatol Sci 2000, 24(Suppl 1):S51–S59.
8. Schneider H, Muhle C, Pacho F: Biological function of laminin-5 and
pathogenic impact of its deficiency. Eur J Cell Biol 2007, 86:701–717.
9. Akutsu N, Amano S, Nishiyama T: Quantitative analysis of laminin 5 gene
expression in human keratinocytes. Exp Dermatol 2005, 14:329–335.
10. Kiritsi D, Has C, Bruckner-Tuderman L: Laminin 332 in junctional
epidermolysis bullosa. Cell Adh Migr 2013, 7:135–141.
11. Amano S, Akutsu N, Ogura Y, Nishiyama T: Increase of laminin 5 synthesis
in human keratinocytes by acute wound fluid, inflammatory cytokines
and growth factors, and lysophospholipids. Br J Dermatol 2004,
151:961–970.
12. Macaluso F, Nothnagel M, Parwez Q, Petrasch-Parwez E, Bechara FG, Epplen
JT, Hoffjan S: Polymorphisms in NACHT-LRR (NLR) genes in atopic
dermatitis. Exp Dermatol 2007, 16:692–698.
13. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm
Venereol 1980, 92:44–47.
14. Bel EH: Clinical phenotypes of asthma. Curr Opin Pulm Med 2004, 10:44–50.
15. De Marco R, Locatelli F, Cerveri I, Bugiani M, Marinoni A, Giammanco G:
Incidence and remission of asthma: a retrospective study on the natural
history of asthma in Italy. J Allergy Clin Immunol 2002, 110:228–235.
16. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 1988,
16:1215.
17. International HapMap Consortium: The International HapMap Project.
Nature 2003, 426:789–796.
18. DeFinetti test for Hardy-Weinberg equilibrium. http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl.
19. Barrett JC: Haploview: Visualization and analysis of SNP genotype data.
Cold Spring Harb Protoc 2009:pdb ip71.
20. Boehringer S, Epplen JT, Krawczak M: Genetic association studies of
bronchial asthma–a need for Bonferroni correction? Hum Genet 2000,
107:197.
21. Menning M, Kufer TA: A role for the Ankyrin repeat containing protein
Ankrd17 in Nod1- and Nod2-mediated inflammatory responses. FEBS Lett
2013, 587:2137–2142.
22. Rousselle P, Beck K: Laminin 332 processing impacts cellular behavior.
Cell Adh Migr 2013, 7:122–134.
23. Norgett EE, Kelsell DP: SPINK5: both rare and common skin disease.
Trends Mol Med 2002, 8:7.
24. McLean WH, Irvine AD: Heritable filaggrin disorders: the paradigm of
atopic dermatitis. J Invest Dermatol 2012, 132:E20–E21.
25. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C,
Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T,Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung
DY, Barnes KC, Beck LA: Tight junction defects in patients with atopic
dermatitis. J Allergy Clin Immunol 2010, 127:773–786.
26. Paternoster L, Standl M, Chen CM, Ramasamy A, Bonnelykke K, Duijts L,
Ferreira MA, Alves AC, Thyssen JP, Albrecht E, Baurecht H, Feenstra B,
Sleiman PM, Hysi P, Warrington NM, Curjuric I, Myhre R, Curtin JA, Groen-
Blokhuis MM, Kerkhof M, Sääf A, Franke A, Ellinghaus D, Fölster-Holst R,
Dermitzakis E, Montgomery SB, Prokisch H, Heim K, Hartikainen AL, Pouta A,
et al: Meta-analysis of genome-wide association studies identifies three
new risk loci for atopic dermatitis. Nat Genet 2012, 44:187–192.
27. Marenholz I, Rivera VA, Esparza-Gordillo J, Bauerfeind A, Lee-Kirsch MA,
Ciechanowicz A, Kurek M, Piskackova T, Macek M, Lee YA: Association
screening in the Epidermal Differentiation Complex (EDC) identifies an
SPRR3 repeat number variant as a risk factor for eczema. J Invest
Dermatol 2011, 131:1644–1649.
28. Bergboer JG, Zeeuwen PL, Irvine AD, Weidinger S, Giardina E, Novelli G, Den
Heijer M, Rodriguez E, Illig T, Riveira-Munoz E, Campbell LE, Tyson J,
Dannhauser EN, O'Regan GM, Galli E, Klopp N, Koppelman GH, Novak N,
Estivill X, McLean WH, Postma DS, Armour JA, Schalkwijk J: Deletion of Late
Cornified Envelope 3B and 3C genes is not associated with atopic
dermatitis. J Invest Dermatol 2010, 130:2057–2061.
29. Bieber T, Cork M, Reitamo S: Atopic dermatitis: a candidate for disease-
modifying strategy. Allergy 2012, 67:969–975.
30. Heimall J, Spergel JM: Filaggrin mutations and atopy: consequences for
future therapeutics. Expert Rev Clin Immunol 2012, 8:189–197.
doi:10.1186/1471-5945-14-17
Cite this article as: Stemmler et al.: Association of variation in the LAMA3
gene, encoding the alpha-chain of laminin 5, with atopic dermatitis in a
German case–control cohort. BMC Dermatology 2014 14:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
